TrialSignal
Clinical trial intelligence report
A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03461146
Status
COMPLETED
Phase
Phase III
Sponsor
Tanabe Pharma Corporation
Executive brief
Investment-Ready Snapshot
Tanabe Pharma Corporation conducted a Phase III trial of MT-6548, an oral tablet, to evaluate its efficacy and safety in hemodialysis patients with anemia not receiving erythropoiesis-stimulating agents (ESAs). The study enrolled 24 participants and aimed to assess hemoglobin (Hb) correction and maintenance.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03461146
Indication
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Modality
small molecule
Target
Anemia associated with chronic kidney disease in hemodialysis subjects
Intervention
MT-6548
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.